464 related articles for article (PubMed ID: 18482737)
1. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.
Young HA; Geier DA; Geier MR
J Neurol Sci; 2008 Aug; 271(1-2):110-8. PubMed ID: 18482737
[TBL] [Abstract][Full Text] [Related]
2. Thimerosal exposure & increasing trends of premature puberty in the vaccine safety datalink.
Geier DA; Young HA; Geier MR
Indian J Med Res; 2010 Apr; 131():500-7. PubMed ID: 20424300
[TBL] [Abstract][Full Text] [Related]
3. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.
Verstraeten T; Davis RL; DeStefano F; Lieu TA; Rhodes PH; Black SB; Shinefield H; Chen RT;
Pediatrics; 2003 Nov; 112(5):1039-48. PubMed ID: 14595043
[TBL] [Abstract][Full Text] [Related]
4. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.
Geier DA; Geier MR
Med Sci Monit; 2005 Apr; 11(4):CR160-70. PubMed ID: 15795695
[TBL] [Abstract][Full Text] [Related]
5. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.
Geier D; Geier MR
Int J Toxicol; 2004; 23(6):369-76. PubMed ID: 15764492
[TBL] [Abstract][Full Text] [Related]
6. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.
Andrews N; Miller E; Grant A; Stowe J; Osborne V; Taylor B
Pediatrics; 2004 Sep; 114(3):584-91. PubMed ID: 15342825
[TBL] [Abstract][Full Text] [Related]
7. A dose-response relationship between organic mercury exposure from thimerosal-containing vaccines and neurodevelopmental disorders.
Geier DA; Hooker BS; Kern JK; King PG; Sykes LK; Geier MR
Int J Environ Res Public Health; 2014 Sep; 11(9):9156-70. PubMed ID: 25198681
[TBL] [Abstract][Full Text] [Related]
8. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines.
Geier DA; Geier MR
Med Sci Monit; 2006 Jun; 12(6):CR231-9. PubMed ID: 16733480
[TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.
Geier DA; Geier MR
Med Sci Monit; 2004 Mar; 10(3):PI33-9. PubMed ID: 14976450
[TBL] [Abstract][Full Text] [Related]
10. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.
Geier DA; Geier MR
J Toxicol Environ Health A; 2006 Aug; 69(15):1481-95. PubMed ID: 16766480
[TBL] [Abstract][Full Text] [Related]
12. Regression of language and non-language skills in pervasive developmental disorders.
Meilleur AA; Fombonne E
J Intellect Disabil Res; 2009 Feb; 53(2):115-24. PubMed ID: 19054269
[TBL] [Abstract][Full Text] [Related]
13. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association.
Heron J; Golding J;
Pediatrics; 2004 Sep; 114(3):577-83. PubMed ID: 15342824
[TBL] [Abstract][Full Text] [Related]
14. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.
Thompson WW; Price C; Goodson B; Shay DK; Benson P; Hinrichsen VL; Lewis E; Eriksen E; Ray P; Marcy SM; Dunn J; Jackson LA; Lieu TA; Black S; Stewart G; Weintraub ES; Davis RL; DeStefano F;
N Engl J Med; 2007 Sep; 357(13):1281-92. PubMed ID: 17898097
[TBL] [Abstract][Full Text] [Related]
15. Perinatal hepatitis B transmission and vaccination timing in a managed care cohort: assessment of the temporary delay in newborn hepatitis B vaccination due to thimerosal content.
Chang S; Begier EM; Schech SD; Venus P; Shatin D; Braun MM; Ball R
Pediatr Infect Dis J; 2007 Apr; 26(4):329-33. PubMed ID: 17414397
[TBL] [Abstract][Full Text] [Related]
16. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.
Parker SK; Schwartz B; Todd J; Pickering LK
Pediatrics; 2004 Sep; 114(3):793-804. PubMed ID: 15342856
[TBL] [Abstract][Full Text] [Related]
17. Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment.
Geier DA; Mumper E; Gladfelter B; Coleman L; Geier MR
Neuro Endocrinol Lett; 2008 Apr; 29(2):272-80. PubMed ID: 18404135
[TBL] [Abstract][Full Text] [Related]
18. A case-control study evaluating the relationship between thimerosal-containing haemophilus influenzae type b vaccine administration and the risk for a pervasive developmental disorder diagnosis in the United States.
Geier DA; Kern JK; King PG; Sykes LK; Geier MR
Biol Trace Elem Res; 2015 Feb; 163(1-2):28-38. PubMed ID: 25382662
[TBL] [Abstract][Full Text] [Related]
19. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.
Geier DA; Geier MR
Pediatr Rehabil; 2003; 6(2):97-102. PubMed ID: 14534046
[TBL] [Abstract][Full Text] [Related]
20. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism.
Price CS; Thompson WW; Goodson B; Weintraub ES; Croen LA; Hinrichsen VL; Marcy M; Robertson A; Eriksen E; Lewis E; Bernal P; Shay D; Davis RL; DeStefano F
Pediatrics; 2010 Oct; 126(4):656-64. PubMed ID: 20837594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
